Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.

[1]  C. Spencer,et al.  Salmeterol/Fluticasone Propionate Combination , 1999, Drugs.

[2]  G. Keating,et al.  Salmeterol/Fluticasone Propionate , 2012, Drugs.

[3]  K. Lyseng-Williamson,et al.  Inhaled Salmeterol/Fluticasone Propionate , 2012, Drugs.

[4]  C. Perry,et al.  Budesonide/Formoterol , 2012, Drugs.

[5]  J. V. van Noord,et al.  Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. , 2010, Respiratory medicine.

[6]  I. McLay,et al.  Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. , 2010, Journal of medicinal chemistry.

[7]  J. Corren,et al.  Budesonide/formoterol in the treatment of asthma , 2008, Expert review of respiratory medicine.

[8]  M. Cazzola,et al.  Novel long‐acting bronchodilators for COPD and asthma , 2008, British journal of pharmacology.

[9]  M. Mammen,et al.  A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor , 2007, Molecular Pharmacology.

[10]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[11]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[12]  J. Castaǹer,et al.  Indacaterol : Asthma therapy prop inn treatment of copd β2-adrenoceptor agonist , 2005 .

[13]  R. Pauwels,et al.  Burden and clinical features of chronic obstructive pulmonary disease (COPD) , 2004, The Lancet.

[14]  M. Cazzola,et al.  The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. , 2004, Pulmonary pharmacology & therapeutics.

[15]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[16]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[17]  P. Barnes,et al.  Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. , 2002, Drugs of today.

[18]  M. Takeuchi,et al.  Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. , 1998, Chemical & pharmaceutical bulletin.

[19]  A. Buist,et al.  Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. , 1997, Chest.

[20]  A. Buist,et al.  In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial , 1994 .

[21]  R. Ahrens,et al.  Albuterol: An Adrenergic Agent for Use in the Treatment of Asthma Pharmacology, Pharmacokinetics and Clinical Use , 1984, Pharmacotherapy.